The material facts
6 During the relevant period, Mr Blumenthal was one of two directors of EverBlu Capital Pty Ltd. The other director was not resident in Australia and was not active in EverBlu. Mr Blumenthal was also the chairman and an Authorised Representative and Responsible Manager of EverBlu. He oversaw and participated in the corporate advisory and stockbroking services provided by EverBlu as holder of an Australian Financial Services Licence (AFSL). He was also indirectly, through a corporate vehicle owned by him, a part owner of EverBlu and, with the other director, the controlling mind of EverBlu.
7 Anglo Menda Pty Ltd was a corporation of which Mr Blumenthal was the sole director and shareholder. Anglo Menda was an Authorised Representative of EverBlu.
8 Creso Pharma Ltd (now known as Melodiol Global Health Ltd) was listed on the Australian Securities Exchange (ASX) from 20 October 2016 to 12 June 2023, ie covering the relevant period. During the relevant period, Mr Blumenthal was a substantial shareholder, non-executive director and chairman of Creso. As at 28 February 2021, Mr Blumenthal's total shareholding in Creso - which was indirectly held through various corporate vehicles owned by him - was valued at approximately $30 million.
9 From at least July 2017, EverBlu provided corporate advisory services to Creso. EverBlu led Creso's initial public offering.
10 EverBlu maintained a suite of internal policies that included procedures directed towards compliance with its AFSL and the general law. By those policies, Mr Blumenthal was prohibited from providing general advice or accepting client instructions in relation to a company of which he was a director and accepting client instructions in relation to a company under "Restriction". Creso was a company under "Restriction" during the relevant period.
11 On 23 March 2021, Mr Blumenthal was placed on the "Chinese Wall" Register (which recorded EverBlu's representatives in possession of non-public information and imposed strict limitations and conditions on the use of that information) with respect to Creso. The addition of Mr Blumenthal to that register generated an automated "Chinese Walls Register Entry Acknowledgement", which required him to acknowledge that he would, amongst other things, not take orders from clients to buy or sell Creso shares and, in the event of receiving such an order, he would "pass the phone to another adviser".
12 Contrary to several of EverBlu's policies, Mr Blumenthal personally and through a Designated Trading Representative (DTR) entered, amended and cancelled multiple client orders for Creso shares directly through client accounts. He also directed the DTR to enter, amend and cancel multiple client orders for Creso shares through the Suspense Account and subsequently book the resulting trades from the Suspense Account to one or more client accounts, each of which was held in the name of individuals known to Mr Blumenthal.
13 The Suspense Account, styled 'SUSP_EVB', was an account typically used for temporary entries in the absence of some information that was needed to properly assign an order to a particular client account.
14 During the relevant period, trades placed through EverBlu accounted for approximately 27% of all market volume for trading in Creso shares. Approximately 75% of those trades were conducted through the Suspense Account.
15 In all, six EverBlu clients' accounts were ultimately allocated Creso shares bought or sold through the Suspense Account. Mr Blumenthal loaned money to three of those six EverBlu clients via Anglo Menda for the purpose of funding the purchase of those Creso shares.
16 A substantial portion of the trades allocated to the six clients were conducted under Mr Blumenthal's instructions to the DTR during the relevant period when Mr Blumenthal was subject to the "Chinese Wall" restriction. It is not alleged that the relevant trade instructions were not provided by each of the clients identified, but rather that they were given effect in breach of EverBlu's policies.
17 On 14 occasions during the relevant period, Mr Blumenthal either by himself or by direction to the DTR disaggregated single client orders for the purchase of Creso shares. That was done using the Suspense Account, save for three occasions when some bids were placed via the Suspense Account and some via the client account of Tyson Scholz. At the time of receiving the client orders, Mr Blumenthal had sought and obtained from the relevant EverBlu clients their authorisation to execute the orders in a manner that he considered appropriate.
18 The trades were disaggregated with the intention, on the part of Mr Blumenthal, of representing to the market that there were more individual bidders for Creso shares than in fact existed, so as to create, or cause the creation of, a false or misleading appearance with respect to the market for Creso shares. The parties are agreed that the conduct was likely to have had the effect of creating, or causing the creation of, a misleading appearance with respect to the number of market participants actively trading Creso shares.
19 As mentioned, Mr Blumenthal was, indirectly, a substantial Creso shareholder and a member of its board. Notwithstanding his obligations to adhere to EverBlu's relevant policies which prohibited such conduct, Mr Blumenthal used his capacity as a broker at EverBlu to place trades for Creso shares in the disaggregated manner referred to above.
20 In or around March 2021, Mr Blumenthal caused Creso to separately engage Mr Scholz and Aldo Sacco to provide Creso with promotional and marketing services. Mr Sacco was also engaged by Creso to consult and to provide market data, market research and market intelligence, which services were to be provided to Mr Blumenthal on behalf of Creso. Mr Sacco was also to promote Creso via his professional and social media network. Both Mr Sacco and his main trading entity were clients of EverBlu.
21 The agreement between Creso and Mr Sacco was not in writing. Mr Sacco did not provide Mr Blumenthal with any formal reports detailing the services he provided.
22 During the relevant period, Mr Sacco, via his company Nandil Pty Ltd, issued invoices to Creso totalling $1,237,500 for his marketing and promotional services. Those invoices were paid by Creso after having been approved by Creso's board of directors on Mr Blumenthal's recommendation.
23 Prior to his engagement by Creso, Mr Scholz was an existing EverBlu client. During the relevant period, via his companies SV4T Investments Pty Ltd and EWOLF Enterprises Pty Ltd, Mr Scholz issued invoices to Creso totalling $2,013,000. Those invoices were paid by Creso after having been approved by Creso's board of directors on Mr Blumenthal's recommendation.
24 During the relevant period, Mr Blumenthal, via his company Anglo Menda, loaned Mr Scholz $7,125,460 to fund the purchase of Creso shares, whilst Mr Scholz was providing Creso with marketing and promotional services. Mr Blumenthal charged Mr Scholz $712,546 in interest on the loans. The financial relationship between Mr Blumenthal and Mr Scholz was not disclosed to the board of Creso from May 2021 to the end of the relevant period. Disclosure of the relationship was made by way of letter from Mr Blumenthal to the board of Creso in September 2022. Also, Mr Blumenthal failed to exclude himself from the board of Creso when the board decided to approve the payment of Mr Scholz's invoices to Creso.
25 I am satisfied that in engaging Mr Scholz and Mr Sacco on behalf of Creso, Mr Blumenthal failed to:
(1) carry out adequate due diligence as to the capacity of those persons to perform the contracted services with Creso;
(2) document the contracted services in writing;
(3) require measurable deliverables such that the service provision could be objectively assessed;
(4) require detailed invoices documenting the services provided;
(5) keep any record of the services being provided to Creso by Mr Sacco and Mr Scholz; and
(6) assess whether the contracted services provided by Mr Sacco and Mr Scholz represented value for money for Creso.